AUSTRALIAN ASSOCIATED PRESS
  • TRUSTED
  • ACCURATE
  • IMPARTIAL
DONATE SUBSCRIBE

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

PRNewswire May 10, 2023
  • Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapy in Europe
  • IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer

PARIS, May 10, 2023 /PRNewswire/ — Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a targeted therapy in two indications: in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy; as well as in monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.

Tibsovo® is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.

“The prognosis for patients diagnosed with acute myeloid leukemia or cholangiocarcinoma has historically been poor with very limited treatment options. With today’s approval by the European Commission, Tibsovo® is now the first targeted IDH1 inhibitor approved in Europe. This further affirms our unparalleled scientific leadership in harnessing the IDH mutation and commitment to finding new therapeutic solutions for patients with difficult and hard-to-treat cancers,” said Arnaud Lallouette, M.D., Executive Vice President, Global Medical & Patient Affairs at Servier.

“IDH1 mutations are major drivers of disease progression in acute myeloid leukemia and cholangiocarcinoma, which are usually diagnosed at an advanced stage, highlighting the urgent need for a targeted therapeutic option. The development of new targeted therapies such as Tibsovo®, which works differently from traditional chemotherapies, is now providing treatment options that may increase the life expectancy and quality of life for patients,” said Philippe Gonnard, M.D., Executive Vice President, Global Product Strategy at Servier.

PDF – https://mma.prnewswire.com/media/2074010/Servier_Tibsovo_EC_Approval.pdf

Media contact:
presse@servier.com

SOURCE Servier

Keep updated

Latest Releases

Latest News

AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.

AAP FactCheck

  • Information you can trust
  • Written by trained, experienced journalists using authoritative sources
  • Accredited by the International Fact-Checking Network (IFCN)

AAP FactCheck provides factual, authoritative information Australians can rely on. Accredited with the Poynter Institute's International Fact-Checking Network and adhering to the highest industry standards, our experienced team works to minimise the impact of misinformation.

AAP Photos

  • Award-winning Australian Photography
  • Editorial or Commercial use
  • Subscriptions or one-off licences

Image buyers from all industries rely on AAP Photos. A digital treasure trove of content depicting Australian life, our fully-searchable database contains millions of images from around the country and around the world.

AAPNews

  • News delivered to your inbox
  • Trusted, reliable and accurate
  • Corporate and individual packages available

AAPNews delivers newswire content direct to the public. Choose from a number of subscription models to not only gain access to high-quality fact-based news on your desktop or mobile device, but also to show your support for Australia's only not-for-profit newswire.

Newsroom

  • The wire – up to the minute news at your fingertips
  • Feeds delivered to your CMS
  • Agenda – AAP’s planning and events tool

Get the news feed your organisation needs, with AAP offering extensive coverage of news, courts, politics, sports, finance and the arts. Take advantage of AAP’s partner content to get the international news that matters to your business, with news feeds delivered via multiple channels including API and FTP.